Srdan Verstovsek
Medical Oncology · Houston, TXNPI 1598864100
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $297,143 of the $463,760 with a category attached, or 64.1%. 23 manufacturers reported payments, led by Incyte Corporation at 40.8% of the total. Reporting peaked in 2022 at $138,597 and has fallen 50.6% since, to $68,441 in 2023. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 217 payments — averaging $2137.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$189K
- Bristol Myers Squibb$36K
- Novartis$32K
- GSK$31K
- Novartis Pharma AG$28K
- NS Pharma, Inc.$22K
- plus $125K from 17 others
Across 463 payments — averaging $5276.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$2.2M
- Bristol Myers Squibb$136K
- AbbVie$51K
- Pharmaessentia USA Corporation$24K
- F. Hoffmann-la Roche AG$8K
- Novartis$655
What the payments were for
- Consulting fees$297,14364%
- Speaking & faculty fees$150,40732%
- Travel & lodging$8,4042%
- Food & beverage$2,4631%
- Education$5,3431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 84 | $189,391 |
| Bristol Myers Squibb | 27 | $36,396 |
| Novartis | 14 | $31,855 |
| GSK | 14 | $30,841 |
| Novartis Pharma AG | 11 | $27,709 |
| NS Pharma, Inc. | 6 | $22,400 |
| E.r. Squibb & Sons, L.L.C. | 8 | $20,413 |
| Karyopharm Therapeutics Inc. | 2 | $19,680 |
| CTI Biopharma Corp. | 6 | $18,429 |
| Ipsen Biopharmaceuticals, Inc | 11 | $16,400 |
| Pharmaessentia USA Corporation | 9 | $14,264 |
| AbbVie | 7 | $7,406 |
| F. Hoffmann-la Roche AG | 3 | $5,940 |
| Blueprint Medicines Corporation | 3 | $5,688 |
| Amgen | 2 | $4,760 |
| Hikma Pharmaceuticals USA | 2 | $4,000 |
| Janssen Research & Development, LLC | 1 | $2,480 |
| Kyowa Kirin, Inc. | 1 | $1,875 |
| Jazz Pharmaceuticals Inc. | 2 | $1,650 |
| Alnylam Pharmaceuticals Inc. | 1 | $1,050 |
| Beigene USA, Inc. | 1 | $1,000 |
| Morphosys, US Inc. | 1 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JAKAFI$50,629
- XPOVIO$19,680
- Vonjo$18,397
- BESREMI$14,165
- Inrebic$12,593
- TASIGNA$11,004
- RYDAPT$10,231
- JAKAVI_JAKAFI_ONCOLOGY$8,249
- PEMAZYRE$7,380
- Reblozyl$6,806
- RUXOLITINIB_JAKAFI_ONCOLOGY$5,502
- Non-Covered Product$5,280
- Kyprolis$4,760
- AYVAKIT$3,448
- NUCALA$3,250
- VILTEPSO$2,100
- Venclexta$1,837
- BRUKINSA$1,000
- Fedratinib$476
- AFINITOR$402
How this compares
$463,760 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
- Eric JonaschHouston$374K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.